AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 23, 2024
32407_dirs_2024-01-22_093c54c9-5c41-44dc-b075-2dfbd0cdfcdb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2024-01-18
Reporting Person: Henderson Molly (CFO and CBO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-19 | Common Stock | S | 6307 | $7.7533 | Disposed | 98698 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-18 | Stock Option (Right to Buy) | $7.60 | A | 120000 | Acquired | 2034-01-17 | Common Stock (120000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1911.27 | Indirect |
Footnotes
F1: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2: Includes 1,944 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024.
F3: The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.